Ticker Report Dyne Therapeutics (NASDAQ:DYN - Get Free Report) was downgraded by investment analysts at StockNews.com from a "hold" rating to a "sell" rating in a report released on Tuesday. A number of other...\n more…
Globe Newswire NEW YORK, Sept. 11, 2024 (GLOBE NEWSWIRE) -- Attorney Advertising--Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Dyne Therapeutics, Inc. ( Dyne or...\n more…
Globe Newswire NEW YORK, Sept. 10, 2024 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, is investigating potential claims against Dyne Therapeutics, Inc...\n more…